NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs
2023年10月11日 - 9:00PM
ビジネスワイヤ(英語)
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare, skincare and
wound care products, announces the launch of two new promotional
programs for ophthalmologists and optometrists who help their
patients manage the symptoms of chronic dry eye with
Avenova®-branded products. Through the new Avenova Loyalty Program
and Avenova Affiliate Program, top Avenova eyecare professionals
will have access to special promotions specifically designed to
increase the awareness of the full suite of Avenova products.
“We have thousands of eye care professionals who recommend,
prescribe, and sell our Avenova spray on a daily basis. These new
promotional programs are meant to reward those top doctors and also
raise awareness around our other products such as warm eye
compress, i-chek, lubricating drops and oral supplements. Avenova
spray is the No. 1 doctor-recommended lid and lash cleanser and we
are delighted to offer these partnership opportunities to grow this
important sales channel,” said Justin Hall, CEO of NovaBay
Pharmaceuticals.
“We regularly hear from eyecare professionals that dry eye is a
major concern for many of their patients and the use of Avenova
spray can help manage the bothersome symptoms related to this
condition,” he added. “We asked our ophthalmologist and optometrist
advisory boards how NovaBay can best serve those patients, with the
result being these new Avenova programs.”
Manufactured in the U.S., Avenova spray is formulated with
NovaBay’s patented, proprietary, stable and pure form of
hypochlorous acid. It is clinically proven to kill a broad spectrum
of bacteria to help relieve the symptoms of bacterial dry eye, yet
is non-irritating and completely safe for regular use. As dry eye
is a complex condition, NovaBay offers a full portfolio of
scientifically developed, best-in-class products for each step of
the standard treatment regimen, including the Avenova Eye Health
Support antioxidant-rich oral supplement, Avenova Lubricating Eye
Drops for instant relief, Avenova Warm Eye Compress to soothe the
eyes and the i-Chek by Avenova to monitor physical eyelid health.
All Avenova products are available directly to consumers through
online distribution channels such as Amazon and Avenova.com.
Ophthalmologists and optometrists interested in learning more
about the new Avenova Loyalty and Affiliate Programs should email
sales@novabay.com or call 510-899-8841.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
consumers through online distribution channels such as Amazon.
DERMAdoctor® offers more than 30 dermatologist-developed skincare
products through the DERMAdoctor website, well-known traditional
and digital beauty retailers, and international distributors.
NovaBay also manufactures and sells effective, yet gentle and
non-irritating wound care products. The PhaseOne® brand is
distributed through commercial partners in the U.S. for
professional use only, and the NeutroPhase® brand is distributed in
China by China Pioneer Pharma Holdings, Limited.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current partnerships, marketing efforts, and any future
revenue that may result from such partnerships and related
marketing initiatives, as well as generally the Company’s expected
future financial results. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to the size of the potential market for our
products, the possibility that the available market for the
Company’s products will not be as large as expected, the Company’s
products will not be able to penetrate one or more targeted
markets, and revenues will not be sufficient to meet the Company’s
cash needs. Other risks relating to NovaBay’s business, including
risks that could cause results to differ materially from those
projected in the forward-looking statements in this press release,
are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231011135830/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 5 2024 まで 6 2024
NovaBay Pharmaceuticals (AMEX:NBY)
過去 株価チャート
から 6 2023 まで 6 2024